Bethlehem-based Saladax acquires patent portfolio from Janssen Pharmaceutica

BETHLEHEM, Pa. – Bethehem-based Saladax Biomedical Inc. has acquired a patent portfolio from Janssen Pharmaceutica NV.

Saladax didn’t disclose phrases of the settlement to accumulate mental property from Janssen, which is a part of Johnson & Johnson. The transaction consists of 17 patent households and, together with Saladax’s current mental property, covers the main antipsychotic medication which might be prescribed worldwide, based on a Saladax press launch. The acquisition offers Saladax a premier place within the antipsychotic drug-testing area, based on the assertion.

“It is a very thrilling time for Saladax and the sphere of therapeutic drug monitoring,” Sal Salamone, founder and chief govt officer of Saladax, mentioned within the assertion. The corporate’s merchandise assist diagnose sufferers who’ve severe psychological sickness.

Saladax says on its web site that since 2007, its expertise has been used to assist monitor affected person care. The corporate additionally works with pharmaceutical firms to develop assessments for medical trials.

“We consider that really customized medication can solely exist when the precise drug is taken on the proper dose,” based on the Saladax web site.

See also  Openings and Closings: Enterprise happenings across the space